Development of Antigen-Specific Memory CD8⁺ T Cells Following Live-Attenuated Chimeric West Nile Virus Vaccination

ChimeriVax-WN02 is a novel live-attenuated West Nile virus (WNV) vaccine containing modified WNV premembrane (prM) and envelope (E) sequences inserted into the yellow fever 17D vaccine genome. We investigated the induction and evolution of CD8⁺ T cell responses to a WNV envelope epitope, which is a...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 203; no. 4; pp. 513 - 522
Main Authors Smith, Heidi L., Monath, Thomas P., Pazoles, Pamela, Rothman, Alan L., Casey, Diane M., Terajima, Masanori, Ennis, Francis A., Guirakhoo, Farshad, Green, Sharone
Format Journal Article
LanguageEnglish
Published Oxford Oxford University Press 15.02.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ChimeriVax-WN02 is a novel live-attenuated West Nile virus (WNV) vaccine containing modified WNV premembrane (prM) and envelope (E) sequences inserted into the yellow fever 17D vaccine genome. We investigated the induction and evolution of CD8⁺ T cell responses to a WNV envelope epitope, which is a dominant target in naturally infected HLA-A*02-positive individuals. WNV epitope-specific CD8⁺ T cells were detected by HLA tetramer staining in 22 of 23 donors tested, with peak frequencies occurring between days 14 and 28. WNV epitope-specific T cells evolved from an effector phenotype to a long-lived memory phenotype. In the majority of donors, CD8⁺ T cells were able to lyse targets expressing WNV envelope protein and produced macrophage inflammatory protein 1β, interferon γ, and/or tumor necrosis factor α following envelope peptide stimulation. WNV E-specific CD8⁺ T cell responses were detected for up to 1 year after vaccination. The evolution of this WNV-specific T cell response is similar to that observed in established, highly immunogenic vaccines.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-News-3
content type line 23
Potential conflicts of interest: F.G. is a current employee and T.P.M. is a former employee of Acambis (now Sanofi Pasteur), which sponsored this study.
Presented in part: 55th annual meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, GA, 12–16 November 2006; 58th annual meeting of the American Society of Tropical Medicine and Hygiene, Washington, DC, 18–22 November 2009.
ISSN:0022-1899
1537-6613
1537-6613
0022-1899
DOI:10.1093/infdis/jiq074